109 related articles for article (PubMed ID: 17761417)
21. Carbamate-appended N-alkylsulfonamides as inhibitors of gamma-secretase.
Bergstrom CP; Sloan CP; Lau WY; Smith DW; Zheng M; Hansel SB; Polson CT; Corsa JA; Barten DM; Felsenstein KM; Roberts SB
Bioorg Med Chem Lett; 2008 Jan; 18(2):464-8. PubMed ID: 18178084
[TBL] [Abstract][Full Text] [Related]
22. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
23. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel sulfonamide-pyrazolopiperidine series as potent and efficacious gamma-secretase inhibitors.
Ye XM; Konradi AW; Smith J; Xu YZ; Dressen D; Garofalo AW; Marugg J; Sham HL; Truong AP; Jagodzinski J; Pleiss M; Zhang H; Goldbach E; Sauer JM; Brigham E; Bova M; Basi GS
Bioorg Med Chem Lett; 2010 Apr; 20(7):2195-9. PubMed ID: 20207136
[TBL] [Abstract][Full Text] [Related]
25. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
Prasad CV; Zheng M; Vig S; Bergstrom C; Smith DW; Gao Q; Yeola S; Polson CT; Corsa JA; Guss VL; Loo A; Wang J; Sleczka BG; Dangler C; Robertson BJ; Hendrick JP; Roberts SB; Barten DM
Bioorg Med Chem Lett; 2007 Jul; 17(14):4006-11. PubMed ID: 17502137
[TBL] [Abstract][Full Text] [Related]
26. A conformational constraint improves a beta-secretase inhibitor but for an unexpected reason.
Hills ID; Holloway MK; de León P; Nomland A; Zhu H; Rajapakse H; Allison TJ; Munshi SK; Colussi D; Pietrak BL; Toolan D; Haugabook SJ; Graham SL; Stachel SJ
Bioorg Med Chem Lett; 2009 Sep; 19(17):4993-5. PubMed ID: 19640712
[TBL] [Abstract][Full Text] [Related]
27. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Cole DC; Stock JR; Chopra R; Cowling R; Ellingboe JW; Fan KY; Harrison BL; Hu Y; Jacobsen S; Jennings LD; Jin G; Lohse PA; Malamas MS; Manas ES; Moore WJ; O'Donnell MM; Olland AM; Robichaud AJ; Svenson K; Wu J; Wagner E; Bard J
Bioorg Med Chem Lett; 2008 Feb; 18(3):1063-6. PubMed ID: 18162398
[TBL] [Abstract][Full Text] [Related]
28. Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
Asberom T; Bara TA; Clader JW; Greenlee WJ; Guzik HS; Josien HB; Li W; Parker EM; Pissarnitski DA; Song L; Zhang L; Zhao Z
Bioorg Med Chem Lett; 2007 Jan; 17(1):205-7. PubMed ID: 17046254
[TBL] [Abstract][Full Text] [Related]
29. Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.
Peters JU; Galley G; Jacobsen H; Czech C; David-Pierson P; Kitas EA; Ozmen L
Bioorg Med Chem Lett; 2007 Nov; 17(21):5918-23. PubMed ID: 17869099
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J
J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors.
Aubele DL; Truong AP; Dressen DB; Probst GD; Bowers S; Mattson MN; Semko CM; Sun M; Garofalo AW; Konradi AW; Sham HL; Zmolek W; Wong K; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Nguyen L; Bova MP; Hemphill SS; Basi G
Bioorg Med Chem Lett; 2011 Oct; 21(19):5791-4. PubMed ID: 21885276
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Kreft AF; Martone R; Porte A
J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
[No Abstract] [Full Text] [Related]
33. Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors.
Truong AP; Aubele DL; Probst GD; Neitzel ML; Semko CM; Bowers S; Dressen D; Hom RK; Konradi AW; Sham HL; Garofalo AW; Keim PS; Wu J; Dappen MS; Wong K; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Nguyen L; Hemphill SS; Bova MP; Bard F; Yednock TA; Basi G
Bioorg Med Chem Lett; 2009 Sep; 19(17):4920-3. PubMed ID: 19660943
[TBL] [Abstract][Full Text] [Related]
34. Design of potent inhibitors of human beta-secretase. Part 2.
Freskos JN; Fobian YM; Benson TE; Moon JB; Bienkowski MJ; Brown DL; Emmons TL; Heintz R; Laborde A; McDonald JJ; Mischke BV; Molyneaux JM; Mullins PB; Bryan Prince D; Paddock DJ; Tomasselli AG; Winterrowd G
Bioorg Med Chem Lett; 2007 Jan; 17(1):78-81. PubMed ID: 17049233
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors.
Li H; Xu R; Cole D; Clader JW; Greenlee WJ; Nomeir AA; Song L; Zhang L
Bioorg Med Chem Lett; 2010 Nov; 20(22):6606-9. PubMed ID: 20933414
[TBL] [Abstract][Full Text] [Related]
37. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
38. Novel orally bioavailable gamma-secretase inhibitors with excellent in vivo activity.
Keown LE; Collins I; Cooper LC; Harrison T; Madin A; Mistry J; Reilly M; Shaimi M; Welch CJ; Clarke EE; Lewis HD; Wrigley JD; Best JD; Murray F; Shearman MS
J Med Chem; 2009 Jun; 52(11):3441-4. PubMed ID: 19432431
[TBL] [Abstract][Full Text] [Related]
39. Substituted 2-oxo-azepane derivatives are potent, orally active gamma-secretase inhibitors.
Kitas EA; Galley G; Jakob-Roetne R; Flohr A; Wostl W; Mauser H; Alker AM; Czech C; Ozmen L; David-Pierson P; Reinhardt D; Jacobsen H
Bioorg Med Chem Lett; 2008 Jan; 18(1):304-8. PubMed ID: 17983746
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of an aminopiperidine series of γ-secretase modulators.
Kobayashi T; Iwama S; Fusano A; Kato Y; Ikeda A; Teranishi Y; Nishihara A; Tobe M
Bioorg Med Chem Lett; 2014 Jan; 24(1):378-81. PubMed ID: 24269163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
